Virtu Financial’s Genocea Biosciences, Inc. GNCA Stock Holding History

Virtu Financial’s Portfolio GNCA Stock Details GNCA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-12,503	Closed	-$15K	–	2495
2021 Q4	$15K	Buy	+12,503	New	+$18.6K	﹤0.01%	1552
2021 Q3	–	Sell	-15,625	Closed	-$37K	–	2362
2021 Q2	$37K	Buy	+15,625	New	+$37.7K	﹤0.01%	1373
2020 Q3	–	Sell	-36,686	Closed	-$84K	–	1803
2020 Q2	$84K	Buy	+36,686	New	+$84.5K	0.01%	925
2019 Q4	$38K	Buy	+18,460	New	+$43.8K	﹤0.01%	1250
2019 Q3	–	Sell	-92,644	Closed	-$363K	–	2066
2019 Q2	$363K	Buy	+92,644	New	+$483K	0.02%	689
2019 Q1	–	Sell	-7,152	Closed	-$16K	–	2115
2018 Q4	$16K	Buy	+7,152	New	+$35.6K	﹤0.01%	1400
2018 Q2	–	Sell	-3,301	Closed	-$28K	–	2757
2018 Q1	$28K	Sell	3,301 -22,955	-87%	-$191K	﹤0.01%	1793
2017 Q4	$244K	Buy	26,256 +893	+4%	+$8.98K	0.01%	1464
2017 Q3	$296K	Buy	+25,363	New	+$963K	0.01%	1397

Other funds holding GNCA

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

KCM

Kingdon Capital Management New York $911M AUM 51.11% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return

AICPI

ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Virtu Financial's GNCA Position: Q1 2022 in Review

Virtu Financial sold out of Genocea Biosciences, Inc. (GNCA) in Q1 2022, closing a stake of 12,503 shares — an estimated $15K sold.

Virtu Financial first reported a position in GNCA in Q3 2017 and held it in 9 quarters. The position peaked at $363K in Q2 2019. 40 funds tracked by Wall St. Rank hold GNCA as of Q1 2022.

Virtu Financial reported no remaining Genocea Biosciences, Inc. position as of Q1 2022 after selling out during the quarter.
Virtu Financial sold 12,503 Genocea Biosciences, Inc. shares in Q1 2022, an estimated $15K.
Virtu Financial first reported a position in Genocea Biosciences, Inc. in Q3 2017 and held it in 9 quarters.
Virtu Financial's Genocea Biosciences, Inc. position peaked at $363K in Q2 2019.
40 funds tracked by Wall St. Rank held Genocea Biosciences, Inc. as of Q1 2022.

Based on Virtu Financial's 13F filing for Q1 2022, filed 17 May 2022.